Kenvue (KVUE) interim CEO Kirk Perry met with secretary of health and human services Robert F. Kennedy Jr. to argue there’s no clear link between Tylenol and autism, ahead of an upcoming report that includes the over-the-counter medication as a potential cause, The Wall Street Journal’s Peter Loftus reports. Kenvue defended Tylenol’s safety for pregnant women, citing a lack of safe alternatives and research, according to a person familiar with the matter. The FDA has not found clear evidence to date that the appropriate use of acetaminophen during pregnancy causes adverse effects, according to its website.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Buy Rating on Kenvue, Inc. Amidst Minimal Legal Risks and Overreaction to Tylenol Concerns
- Kenvue price target lowered to $23 from $25 at Evercore ISI
- Kenvue Inc put buyer realizes 365% same-day gains
- Positive Buy Rating for Kenvue, Inc. Amid Favorable Legal and Regulatory Developments
- BofA sees ‘particularly attractive entry point’ after Kenvue pullback